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(57) ABSTRACT 
Compounds useful for inhibiting the immunoproteasome 
have the formula of 
R......_ 
N 
H 
Rx 
Ry. 
Methods and compounds for inhibiting the immunoprotea-
some, particularly, immunoproteasome inhibitors with non-
peptide scaffolds, are described. 
13 Claims, 2 Drawing Sheets 
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SELECTIVE IMMUNOPROTEASOME 
INHIBITORS WITH NON-PEPTIDE 
SCAFFOLDS 
RELATED APPLICATIONS 
This application claims priority from U.S. Provisional 
Application Ser. No. 62/162,324 filed May 15, 2015, the 
entire disclosure of which is incorporated herein by this 
reference. 
GOVERNMENT INTEREST 
10 
2 
Therefore, it is highly desirable to identify unique com-
pounds with non-peptide scaffolds that can selectively 
inhibit the immunoproteasome 35i. 
SUMMARY 
The presently-disclosed subject matter meets some or all 
of the above-identified needs, as will become evident to 
those of ordinary skill in the art after a study of information 
provided in this document. 
This Summary describes several embodiments of the 
presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. This 
Summary is merely exemplary of the numerous and varied 
embodiments. Mention of one or more representative fea-
This invention was made with govermnent support under 
RC1MH088480 and R01CA128903 awarded by the 
National Institutes of Health. The govermnent has certain 
rights in the invention. 
TECHNICAL FIELD 
15 tures of a given embodiment is likewise exemplary. Such an 
embodiment can typically exist with or without the 
feature(s) mentioned; likewise, those features can be applied 
to other embodiments of the presently-disclosed subject 
matter, whether listed in this Summary or not. To avoid 
excessive repetition, this Summary does not list or suggest 
20 all possible combinations of such features. 
As noted hereinabove, it is highly desirable to identify 
unique, immunoproteasome-selective inhibitors with non-
peptide scaffolds. 
Through combined virtual screening and experimental 
The presently-disclosed subject matter relates to inhibi-
tion of the immunoproteasome. In particular, the presently-
disclosed subject matter relates to immunoproteasome 
inhibitors with non-peptide scaffolds. 
INTRODUCTION 
25 studies targeting the immunoproteasome, the present inven-
tors have identified a set of immunoproteasome inhibitors 
with diverse non-peptide scaffolds. Some of the identified 
inhibitors have significant selectivity for the immunoprotea-
some over the constitutive proteasome. Unlike most of the Proteasome plays a central role in maintaining cellular homeostasis, controlling the cell cycle, removing misfolded 
proteins that can be toxic, and regulating the immune 
system. 1 This crucial protein degradation machinery has 
been implicated in multiple diseases such as Alzheimer's 
disease, Huntington's disease (HD), inflammatory bowel 
diseases (IBD), autoimmune diseases, multiple myeloma 
(MM) and other cancers.2 In particular, proteasome has been 
recognized as a promising cancer target, and the Food and 
Drug Administration (FDA) has approved proteasome 
inhibitors bortezomib (Velcade®) in 2003 and carfilzomib 
(Kyprolis®) in 2012 for the MM treatment. The FDA 
approvals of these proteasome inhibitors as chemotherapeu- 40 
tic agents have dramatically improved the therapeutic land-
scape for patients with MM.3 
30 currently available proteasome inhibitors, these new inhibi-
tors lacking electrophilic pharmacophores are not contem-
plated to form a covalent bond with proteasome after the 
binding. These non-peptide scaffolds are useful for targeting 
the immunoproteasome. 
The presently-disclosed subject matter includes com-
35 pounds, compositions, and methods useful for inhibiting 
immunoproteasome. The presently-disclosed inhibitors are 
compounds have non-peptide scaffolds. In some embodi-
ments, the compound has the structure of the formula (I): 
Despite the remarkable successes of these proteasome 
inhibitors in the clinic, intrinsic and acquired drug resistance 
remains a major clinical challenge. Inhibitors that are pep- 45 
tide backbone-based also have relatively short half-lives 
when administered to a subject. In addition, these drugs have 
failed to provide clinical benefit to patients with solid 
cancers,4 - 6 further highlighting the need for next-generation 
of proteasome inhibitors. 50 
There are two main proteasome subtypes: the constitutive 
proteasome (CP) which is expressed in all eukaryotic cells 
and the immunoproteasome (IP) which is expressed in 
immune cells and can be induced in other cell types. 
Constitutive proteasome contains three catalytic subunits 55 
denoted as 31, 32, and 35, whereas the three corresponding 
catalytic subunits of immunoproteasome are denoted as 31 i, 
32i, and 35i. The catalytic subunits responsible for the 
chymotrypsin-like (CT-L) activity (35 and 35i) are thought 
to be most physiologically important and have been recog-
nized as the key targets of bortezomib and carfilzomib.7 •8 60 
However, these drugs have failed to achieve efficacy in 
patients with solid cancers despite strong indications of 
activity in preclinical animal models. The failure of these 
drugs has been attributed to their poor metabolic stability.9 
Further, recent reports revealed the importance of targeting 65 
the immunoproteasome catalytic subunit 35i in killing can-
cer cells.8 
(I) 
Rx 
Ry 
In some embodiments of the compound of formula (I) the 
compound has the structure of formula (IA): 
(IA) p 
NH 
0 
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In some embodiments of the compound of formula (I) the 
compound has the structure of formula (IB): 
4 
FIG. 1. Dose-dependent inhibition of the innnunoprotea-
some CT-L activity (initial velocity) by compounds 1-3: 
plots of the remaining CT-L activity versus the inhibitor 
concentration. 
(IB) 5 FIG. 2A and FIG. 2B. Binding structures of the innnu-
0 Rx Clli' I ~ 
,,::::; 
noproteasome interacting with compounds 1 (FIG. 2A) and 
3 (FIG. 2B). Indicated in the figures are the key distances 
(A) of the protein-ligand interactions in the energy-mini-
mized structures. Indicated in parentheses is the percent of 
10 the snapshots with the H ... 0 distance shorter than 2.5 A 
in the MD-simulated binding structure. 
0 
In some embodiments, the compound has the structure of 
the formula (II): 
15 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
(II) 20 skill in the art after a study of the information provided in 
this document. The information provided in this document, 
and particularly the specific details of the described exem-
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
25 understood therefrom. In case of conflict, the specification of 
this document, including definitions, will control. 
Rn 
The presently-disclosed subject matter includes com-
pounds, compositions, and methods useful for inhibiting 
innnunoproteasome. The presently-disclosed inhibitors are 
30 
compounds have non-peptide scaffolds. In some embodi-
ments, the compound has the structure of the formula (I): 
The presently-disclosed subject matter includes compo-
sitions that include a compound as described herein. In some 
embodiments the composition includes a compound of for- 35 
mula (I) or a pharmaceutically-acceptable salt thereof. In 
some embodiments the composition includes a compound of 
formula (II) or a pharmaceutically-acceptable salt thereof. In 
some embodiments the composition includes a compound 
selected from compounds 1-19, or a pharmaceutically-ac- 40 
ceptable salt thereof, as set forth in Table lB. 
The presently-disclosed subject matter includes methods 
of inhibiting innnunoproteasome activity. In some embodi-
ments a method of inhibiting innnunoproteasome activity 
involves administering a compound or a composition as 
described herein. In some embodiments a method of inhib- 45 
iting innnunoproteasome activity involves administering a 
compound of formula (I), or a composition comprising a 
compound of formula (I) or a pharmaceutically-acceptable 
salt thereof. In some embodiments a method of inhibiting 
immunoproteasome activity involves administering a com- 50 
pound of formula (II), or a composition comprising a 
compound of formula (II) or a pharmaceutically-acceptable 
salt thereof. In some embodiments a method of inhibiting 
immunoproteasome activity involves administering a com-
pound selected from compounds 1-19, or a composition 55 
comprising a compound selected from compounds 1-19 or a 
pharmaceutically-acceptable salt thereof, as set forth herein. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The novel features of the invention are set forth with 
particularity in the appended claims. A better understanding 
of the features and advantages of the present invention will 
60 
be obtained by reference to the following detailed descrip-
tion that sets forth illustrative embodiments, in which the 65 
principles of the invention are used, and the accompanying 
drawings of which: 
(I) 
Rx 
Ry 
wherein R can be 
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US 9,586,946 B2 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
8 
, or 
In some embodiments of the compound of formula (I), Ry 
IS 
In some embodiments of the compound of formula (I), Rx is 
In some embodiments of the compound of formula (I) the 
compound has the structure of formula (IA): 
R....._ 
N 
H 
p 
NH 
0 j 
(IA) 
~ ~ wherein R is selected from the group consisting of :-1 ,~ l)_)'~ l)' 60 
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In some embodiments of the compound of formula (I), R 
IS 
In some embodiments of the compound of formula (I) the 
compound has the structure of formula (IB): 
11 
-continued 
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In some embodiments of the compound of formula (I) the 
compound has the structure of formula (IB) wherein Rx is 
30 selected from the group consisting of 
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55 
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In some embodiments of the compound of formula (I) the 
compound has the structure of formula (IB) wherein Rx is 
In some embodiments of the compound of formula (I) the 
compound has the structure of formula (IB) wherein Rx is 
15 
selected from the group consisting of 
In some embodiments of the compound of formula (I) the 
compound has the structure of formula (IB) wherein Rx is 
In some embodiments of the compound of formula (I) the 
compound has the structure of formula (IB) wherein Rx is 
20 
25 In some embodiments of the compound of formula (I) the 
compound has the structure of formula (IB) wherein Rx is 
I 
30 0 
35 
In some embodiments, the compound has the structure of 
40 the formula (II): 
(II) 
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50 
55 
wherein RA can be 
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As noted herein above, the presently-disclosed subject 
matter includes compositions that include a compound as 
described herein. In some embodiments the composition 65 
includes a compound of formula (I) or a pharmaceutically-
acceptable salt thereof. In some embodiments the composi-
18 
tion includes a compound of formula (II) or a pharmaceu-
tically-acceptable salt thereof. In some embodiments the 
composition includes a compound selected from compounds 
1-19, or a pharmaceutically-acceptable salt thereof: 
p 
NH 
0 
O~// 
0-d'~ 
2 
OH 
OH 
4 
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Compositions of the presently-disclosed subject matter 
can further include a pharmaceutically-acceptable carrier. As 
65 used herein, the term "pharmaceutically acceptable carrier" 
refers to sterile aqueous or nonaqueous solutions, disper-
sions, suspensions or emulsions, as well as sterile powders 
US 9,586,946 B2 
23 24 
tion, including injectable such as intravenous administra-
tion, intra-arterial administration, intramuscular administra-
tion, and/or subcutaneous administration. Administration 
can be continuous or intermittent. A preparation can be 
administered therapeutically; that is, administered to treat an 
existing condition of interest. A preparation can be admin-
istered prophylactically; that is, administered for prevention 
of a condition of interest. 
In some embodiments a subject will be administered an 
for reconstitution into sterile injectable solutions or disper-
sions just prior to use. Examples of suitable aqueous and 
nonaqueous carriers, diluents, solvents or vehicles include 
water, ethanol, polyols (such as glycerol, propylene glycol, 
polyethylene glycol and the like), carboxymethylcellulose 
and suitable mixtures thereof, vegetable oils (such as olive 
oil) and injectable organic esters such as ethyl oleate. Proper 
fluidity can be maintained, for example, by the use of 
coating materials such as lecithin, by the maintenance of the 
required particle size in the case of dispersions and by the 
use of surfactants. These compositions can also contain 
adjuvants such as preservatives, wetting agents, emulsifying 
agents and dispersing agents. Prevention of the action of 
microorganisms can be ensured by the inclusion of various 
antibacterial and antifungal agents such as paraben, chlo- 15 
robutanol, phenol, sorbic acid and the like. It can also be 
desirable to include isotonic agents such as sugars, sodium 
chloride and the like. Prolonged absorption of the injectable 
pharmaceutical form can be brought about by the inclusion 
10 effective amount of at least one compound and/or compo-
sition provided in the present disclosure. In this respect, the 
term "effective amount" refers to an amount that is sufficient 
to achieve the desired result or to have an effect on an 
of agents, such as aluminum monostearate and gelatin, 20 
which delay absorption. Injectable depot forms are made by 
forming microencapsule matrices of the drug in biodegrad-
able polymers such as polylactide-polyglycolide, poly(or-
thoesters) and poly(anhydrides). Depending upon the ratio 
of drug to polymer and the nature of the particular polymer 25 
employed, the rate of drug release can be controlled. Depot 
injectable formulations are also prepared by entrapping the 
drug in liposomes or microemulsions which are compatible 
with body tissues. The injectable formulations can be ster-
ilized, for example, by filtration through a bacterial-retaining 30 
filter or by incorporating sterilizing agents in the form of 
sterile solid compositions which can be dissolved or dis-
persed in sterile water or other sterile injectable media just 
prior to use. Suitable inert carriers can include sugars such 
as lactose. Desirably, at least 95% by weight of the particles 35 
of the active ingredient have an effective particle size in the 
range of 0.01 to 10 micrometers. 
As noted herein above, the presently-disclosed subject 
matter includes methods of inhibiting immunoproteasome 
activity and methods of selectively inhibit the immunopro- 40 
teasome 35i. In some embodiments a method of inhibiting 
immunoproteasome activity involves administering a com-
pound or a composition as described herein. In some 
embodiments a method of inhibiting immunoproteasome 
activity involves administering a compound of formula (I), 45 
or a composition comprising a compound of formula (I) or 
a pharmaceutically-acceptable salt thereof. In some embodi-
ments a method of inhibiting immunoproteasome activity 
involves administering a compound of formula (II), or a 
composition comprising a compound of formula (II) or a 50 
pharmaceutically-acceptable salt thereof. In some embodi-
ments a method of inhibiting immunoproteasome activity 
involves administering a compound selected from com-
pounds 1-19, or a composition comprising a compound 
selected from compounds 1-19 or a pharmaceutically-ac- 55 
ceptable salt thereof, as set forth herein. 
Unless otherwise indicated, the term "administering" is 
inclusive of all means known to those of ordinary skill in the 
art for providing a preparation to a subject, including admin-
istration by inhalation, nasal administration, topical admin- 60 
istration, intravaginal administration, ophthalmic adminis-
tration, intraaural administration, intracerebral 
administration, intravitreous administration, intracameral 
administration, posterior sub-Tenon administration, poste-
rior juxtascleral administration, subretinal administration, 65 
suprachoroidal administration, cell-based administration or 
production, rectal administration, and parenteral administra-
undesired condition. For example, a "therapeutically effec-
tive amount" refers to an amount that is sufficient to achieve 
the desired therapeutic result or to have an effect on unde-
sired symptoms, but is generally insufficient to cause 
adverse side effects. The specific therapeutically effective 
dose level for any particular patient will depend upon a 
variety of factors including the disorder being treated and 
the severity of the disorder; the specific composition 
employed; the age, body weight, general health, sex and diet 
of the patient; the time of administration; the route of 
administration; the rate of excretion of the specific com-
pound employed; the duration of the treatment; drugs used 
in combination or coincidental with the specific compound 
employed and like factors well known in the medical arts. 
For example, it is well within the skill of the art to start doses 
of a compound at levels lower than those required to achieve 
the desired therapeutic effect and to gradually increase the 
dosage until the desired effect is achieved. If desired, the 
effective daily dose can be divided into multiple doses for 
purposes of administration. Consequently, single dose com-
positions can contain such amounts or submultiples thereof 
to make up the daily dose. The dosage can be adjusted by the 
individual physician in the event of any contraindications. 
Dosage can vary, and can be administered in one or more 
dose administrations daily, for one or several days. Guidance 
can be found in the literature for appropriate dosages for 
given classes of pharmaceutical products. In further various 
aspects, a preparation can be administered in a "prophylac-
tically effective amount"; that is, an amount effective for 
prevention of a disease or condition. 
In some embodiments of the presently-disclosed subject 
matter, the inhibitor is administered in vitro or in a cultured 
cell. 
The terms "subject" or "subject in need thereof' refer to 
a target of administration, which optionally displays symp-
toms related to a particular disease, pathological condition, 
disorder, or the like. The subject of the herein disclosed 
methods can be a vertebrate, such as a mammal, a fish, a 
bird, a reptile, or an amphibian. Thus, the subject of the 
herein disclosed methods can be a human, non-human 
primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea 
pig or rodent. The term does not denote a particular age or 
sex. Thus, adult and newborn subjects, as well as fetuses, 
whether male or female, are intended to be covered. A 
patient refers to a subject afllicted with a disease or disorder. 
The term "subject" includes human and veterinary subjects. 
In some embodiments of the presently-disclosed subject 
matter, the immunoproteasome inhibition can be useful for 
treating a cancer or other condition, such as Alzheimer's 
disease, Huntington's disease (HD), inflammatory bowel 
diseases (IBD), autoimmune diseases, or multiple myeloma 
(MM). 
As used herein, the terms "treatment" or "treating" relate 
to any treatment of a condition, including but not limited to 
US 9,586,946 B2 
25 
prophylactic treatment to prevent development or reduce 
severity of a disorder. The terms "treatment" or "treating" 
include: (1) preventing a condition from occurring in a 
subject who may be predisposed to the; (2) inhibiting the 
condition, i.e., arresting their development; (3) ameliorating 
or relieving the symptoms of the condition; and (4) causing 
regression of the condition. 
As will be recognized by one of ordinary skill in the art, 
the term "inhibiting" or "inhibition" does not refer to the 
ability to completely inactivate all target biological activity 10 
in all cases. Rather, the skilled artisan will understand that 
the term "inhibiting" refers to decreasing biological activity 
of a target. Such decrease in biological activity can be 
determined relative to a control, wherein an inhibitor is not 
administered and/or placed in contact with the target. For 15 
example, in some embodiments, a decrease in activity 
relative to a control can be about a 1, 2, 3, 4, 5, 6, 7, 8, 9, 
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 
26,27, 28,29,30, 31, 32,33,34, 35,36,37,38, 39,40,41, 
42,43, 44,45,46, 47, 48,49, 50, 51, 52, 53, 54, 55, 56, 57, 20 
58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 
74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 
90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% decrease. 
While the terms used herein are believed to be well 
understood by those of ordinary skill in the art, certain 25 
definitions are set forth to facilitate explanation of the 
presently-disclosed subject matter. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as is commonly 
understood by one of skill in the art to which the invention(s) 30 
belong. 
All patents, patent applications, published applications 
and publications, GenBank sequences, databases, websites 
and other published materials referred to throughout the 
entire disclosure herein, unless noted otherwise, are incor- 35 
porated by reference in their entirety. 
Where reference is made to a URL or other such identifier 
26 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia-
tions of in some embodiments ±20%, in some embodiments 
±10%, in some embodiments ±5%, in some embodiments 
±1 %, in some embodiments ±0.5%, and in some embodi-
ments ±0.1 % from the specified amount, as such variations 
are appropriate to perform the disclosed method. 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, ifthe value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, if 10 
and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
The presently-disclosed subject matter is further illus-
trated by the following specific but non-limiting examples. 
The following examples may include compilations of data 
that are representative of data gathered at various times 
during the course of development and experimentation 
related to the present invention. 
EXAMPLES 
Disclosed herein are non-peptide scaffolds of selective 
inhibitors of the immunoproteasome. Exemplary inhibitors 
are set forth in these Examples. 
Virtual Screening 
As disclosed herein, exemplary compounds including 
diverse non-peptide scaffolds, which were identified through 
combined virtual screening and experimental studies target-
ing the catalytic subunit 35i (which is also known as LMP7). 
The virtual screening was based on the present inventors' 
previously-modeled three-dimensional (3D) structure of the 
immunoproteasome, 10- 12 and performed on a compound 
library at Genomics Research Institute (GM), the University 
or address, it understood that such identifiers can change and 
particular information on the internet can come and go, but 
equivalent information can be found by searching the inter-
net. Reference thereto evidences the availability and public 
dissemination of such information. 
40 of Cincinnati (UC). The UC/GRI compound library contain-
ing structural information for about 300,000 compounds was 
provided by Procter & Gamble (P&G) and belonged to a 
consortium including the University of Kentucky as a mem-
ber. 
As used herein, the abbreviations for any protective 
groups, amino acids and other compounds, are, unless 
indicated otherwise, in accord with their common usage, 45 
recognized abbreviations, or the IUPAC-IUB Commission 
on Biochemical Nomenclature (see, Biochem. (1972) 11(9): 
1726-1732). 
Although any methods, devices, and materials similar or 
equivalent to those described herein can be used in the 50 
practice or testing of the presently-disclosed subject matter, 
representative methods, devices, and materials are described 
herein. 
The virtual screening procedure utilized to screen the 
chemical compound library is essentially similar to that 
which the present inventors used to identify small-molecule 
inhibitors of other proteins. 13014 The 300,000 compounds 
were first screened by using a structure-based virtual screen-
ing approach, 13•15 leading to identification of top-25,000 
compounds. The subsequent energy-minimization and 
Molecular Mechanics/Generalized Born Surface Area (MM/ 
GBSA) binding energy calculations using Amberg soft-
ware16 led to identification of the top-1000 compounds. Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
ence to "a cell" includes a plurality of such cells, and so 
forth. 
55 Further structural analysis on possible interactions with key 
amino-acid residues (including Thrl, Ser21, Ser27, Gly47, 
Ala49, and Asp324) led to selection of the top-130 com-
pounds that could inhibit the immunoproteasome. 
Testing Inhibitory Activity 
The computationally selected 13 compounds were tested 
for their inhibitory activity against the CT-L activity of the 
immunoproteasome. The identified active compounds were 
also tested for their inhibitory activity against the CT-L 
activity of the constitutive proteasome. For the initial activ-
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 60 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently-
disclosed subject matter. 
65 ity screening, the selected compounds were dissolved in 
DMSO and used at a concentration of 5 µM. Epoxomicin (1 
tM), which reached the 100% inhibition, was used as a 
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positive control. 20S human immunoproteasome and con-
stitutive proteasome (Boston Biochem) were 2-fold diluted 
in an assay buffer (20 mM Tris/Cl, pH 8.0, 0.5 mM EDTA, 
0.035% SDS).17 
Specifically, selected compounds were preincubated with 
50 ng/well of the immunoproteasome or constitutive pro-
teasome in a 96-well plate at room temperature for 13 min. 
100 µM ofSuc-LLVY-AMC, a fluorogenic peptide substrate 
for the CT-L activity, was then added to the wells. Fluoro- 10 
genie signals of the free AMC (Ex: 360, Em: 460)18 were 
recorded for 90 min. The initial reaction velocities (RFU/ 
min) of each compound were calculated as a percentage of 
the positive control. All enzyme activity assays were carried 
out in triplicate. 15 
Inhibitor Selectivity 
According to the activity assays, nine of the tested com-
pounds (1-19) showing the significant inhibition against the 
immunoproteasome are listed in Table IA for their activity 20 
data and depicted in Table IB for their molecular structures. 
The hit rate of the virtual screening was I 0%. Based on the 
activity data in Table IA, compounds 1-3 at 5 µM inhibited 
the CT-L activity of the immuno-proteasome by about 
36-85%, whereas these compounds at 5 inhibited the con- 25 
stitutive proteasome by only 2-20%. 
This indicates that compounds 1-3 are highly selective 
inhibitors for the immunoproteasome. In particular, com-
pounds I and 3 at 5 µM inhibited the immunoproteasome by 
30 85-62%, respectively. These most potent two compounds, 
along with compound 2, were tested further for the dose-
dependent inhibition (FIG. 1) in order to determine their 
IC50 values (Table IA) against the immunoproteasome. As 
shown in Table IA, the IC50 values for compounds I to 3 are 35 
1.7, 22, and 4.9 respectively. These compounds, particularly 
compounds I and 3, are promising immunoproteasome 
inhibitors with non-peptide scaffolds. 
TABLE IA 
The inhibitory activities of the identified 19 compounds against 
immunoproteasome (IP) and constructive proteasome (CP) - their 
activities for substrate epoxomicin (1 µM). The inhibitory 
activities were characterized as the remaining enzyme activity 
40 
(%) in the presence of the inhibitor at 5 µM. 45 
Compound 
(of Table lB) % IP activity (IC50)"'b % CP activitya 
15 (1.7 µM) 80 
2 64 (22 µM) 98 
38 (4.9 µM) 85 
4 79 98 
81 82 
86 94 
7 65 76 
90 106 
9 87 86 
10 82 85 
11 80 80 
12 69 72 
13 91 88 
14 70 76 
15 74 80 
16 42 50 
17 42 41 
18 75 84 
19 69 67 
aTbe remaining activity(%) of the enzyme in the presence of the inhibitor at 5 µM. 
bTbe determined IC50 values are given in parentheses. 
50 
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TABLE 1B 
Structures of the identified 19 compounds against 
immunoproteasome (IP) and constructive proteasome (CP). 
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TABLE lB-continued 
Structures of the identified 19 compounds against 
immunoproteasome (IP) and constructive proteasome (CP). 
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TABLE lB-continued 
Structures of the identified 19 compounds against 
immunoproteasome (IP) and constructive proteasome (CP). 
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TABLE lB-continued 
Structures of the identified 19 compounds against 
immunoproteasome (IP) and constructive proteasome (CP). 
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TABLE lB-continued 
Structures of the identified 19 compounds against 
immunoproteasome (IP) and constructive proteasome (CP). 
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0 
Immunoproteasome Binding 
Cl, 
Depicted in FIG. 2A and FIG. 2B are the energy-mini-
mized structures of the immunoproteasome binding with 
65 compounds 1 and 3. As shown in FIG. 2A, compound 1 has 
favorable hydrophilic interactions with amino-acid residues 
Thrl, Ser21, Ser27, and Gly47, including strong hydrogen 
US 9,586,946 B2 
33 
bonds with the NH group of Ser21 backbone, hydroxyl 
group of Ser27 side chain, and carbonyl oxygen of Gly47 
backbone. As shown in FIG. 2B, compound 3 has favorable 
hydrophilic interactions with Ser21, Ser27, Ala49, and 
Asp324, including hydrogen bonds with the NH group of 5 
Ser21 backbone and carboxylate oxygen of Asp324 side 
chain. Notably, the H ... 0 distance with the hydroxyl 
oxygen of Ser27 side chain is as long as 3.6 A in the 
energy-minimized structure. 
Further, molecular dynamics (MD) simulation was car- 10 
ried out to examine the dynamically stable binding struc-
tures using the same computational protocol (starting from 
the energy-minimized structures) as used in previous com-
putational studies on immunoproteasome-ligand binding.10• 15 
11 For each inhibitor (compound 1 or 3) binding with 
immunoproteasome, a stable MD trajectory was obtained for 
1 ns and 1000 snapshots were saved (one snapshot per ps) 
for structural analysis. Based on the MD trajectory with 
compound 3, the H ... 0 distance with the hydroxyl oxygen 20 
of Ser27 side chain is shorter than 2.5 A for -15% of the 
snapshots. So, when 2.5 A is used as the cutoff for the 
H ... 0 distance in the hydrogen bonding, it can be said that 
the hydroxyl oxygen of Ser27 side chain has -15% hydro-
gen bond with compound 3 (as indicated in FIG. 2B) and 25 
-93% hydrogen bond with compound 1 (as indicated in FIG. 
2A). 
Notably, Ser21 and Ser27 are common residues of the 
immuno-proteasome that have favorable interactions with 
both compounds 1 and 3. Ser21 and Ser27 in the immuno- 30 
proteasome become Thr21 and Ala27, respectively, in the 
constitutive proteasome. The other residues of the immuno-
proteasome interacting with compounds 1 and 3 are essen-
tially the same as the corresponding ones of the constitutive 
proteasome. So, the selectivity of these new inhibitors for 35 
the immunoproteasome over the constitutive proteasome is 
likely associated with the favorable interaction between the 
inhibitors and the hydroxyl group of Ser27 side chain in the 
immunoproteasome. For the purpose of verification of this 
point, we also modeled constitutive proteasome binding 40 
with compounds 1 and 3 in the same way as we did for 
immunoproteasome with the same compounds, and we 
concluded that each compound binds with both proteins in 
the similar orientation, but without a hydrogen bond with 
Ala27 of constitutive proteasome (because Ala27 does not 45 
have a hydroxyl group on the side chain; data not shown). 
Unlike currently available proteasome inhibitors in clinic, 
these new immunoproteasome inhibitors are non-peptide 
scaffold-based. In addition, these non-peptide scaffold-based 
compounds are contemplated to reversibly inhibit protea- 50 
sames due to the lack ofreactive electrophilic pharmacoph-
ors. 
The present inventors contemplated additional potent and 
selective inhibitors designed to enhance the favorable inter-
actions with all of the amino-acid residues mentioned above. 55 
Particularly, enhancement of the favorable interaction with 
Ser27 of the immunoproteasome is expected to improve 
both the potency and selectivity of the immunoproteasome 
inhibitors. 
The present inventors contemplate unique compounds 60 
that make use of the non-peptide scaffolds of the 19 exem-
plary compounds identified in this Example. Such com-
pounds can be synthesized and tested to improve the inhibi-
tory activity and selectivity. Thus, the present inventors 
contemplate use of compounds including these non-peptide 65 
scaffolds as immunoproteasome inhibitors for use as thera-
peutic agents. 
34 
Inhibitory Activity 
Unique candidate inhibitors were synthesized and tested 
for their inhibitory activity. The tested candidate inhibitors 
are set forth in Table 2, Table 3, and Table 4. 
R, 
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All publications, patents, and patent applications men-
65 tioned in this specification are herein incorporated by ref-
erence to the same extent as if each individual publication, 
patent, or patent application was specifically and individu-
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ally indicated to be incorporated by reference, including the 
references set forth in the following list: 
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It will be understood that various details of the presently 
disclosed subject matter can be changed without departing 
from the scope of the subject matter disclosed herein. 65 
Furthermore, the foregoing description is for the purpose of 
illustration only, and not for the purpose of limitation. 
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6. The compound of claim 5, wherein Rx is selected from 
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9. The compound of claim 5, wherein Rx is 
10. The compound of claim 5, wherein Rx is 
I o. 
11. A pharmaceutical composition for use in inhibiting 
immunoproteasome activity, comprising a compound 
according to claim 1, or a pharmaceutically-acceptable salt 
thereof, and a pharmaceutically-acceptable carrier or excipi-
30 ent. 
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13. A pharmaceutical composition for use in inhibiting 
immunoproteasome activity, comprising a compound 
60 according to claim 12, or a pharmaceutically-acceptable salt 
thereof, and a pharmaceutically-acceptable carrier or excipi-
ent. 
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